Document is current

Article History

Received: 3 November 2022

Revised: 25 January 2023

Accepted: 9 February 2023

First Online: 26 April 2023

Declarations

:

: The scientific guarantor of this publication is Chuantao Zuo from Department of Nuclear Medicine & PET Center & National Center for Neurological Disorders & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China. His email address is zuochuantao@fudan.edu.cn.

: One author of this manuscript declares relationship with the following company: Tzu-Chen Yen is an employee of APRINOIA Therapeutics Co., Ltd (Suzhou, China). All other authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

: No complex statistical methods were necessary for this paper.

: Written informed consent was obtained from all subjects in this study and was waived by the Institutional Review Boards of Huashan Hospital, Fudan University (Shanghai, China), the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China), and the Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (Beijing, China).

: Institutional Review Board approval was obtained from Huashan Hospital, Fudan University (Shanghai, China), the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China), and the Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (Beijing, China).

: Some patients with Alzheimer’s disease (AD, <i>n</i> = 25) have been previously reported in <i>Clin Chem</i>. 2021 Nov 26;67(12):1628–1639 (). The prior report established AD diagnostic models using plasma biomarkers for Chinese participants. Some cognitively unimpaired subjects (<i>n</i> = 15) and some patients with frontotemporal lobar degeneration with cognitive impairment (<i>n</i> = 7) have been previously reported in <i>Mov Disord</i>. 2022 Mar;37(3):525–534 (DOI: 10.1002/mds.28867. The prior report preliminarily investigated the clinical utility of ¹⁸F-florzolotau (¹⁸F-APN-1607) PET in detecting tau accumulation in microtubule-associated protein tau mutation carriers. The current study aimed to develop an ¹⁸F-florzolotau-specific template for MRI-free tau PET imaging in patients with AD, which was different from the above publications.

: